{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:44:22Z","timestamp":1785764662164,"version":"3.56.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13473-6","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T13:13:21Z","timestamp":1780751601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The global scope of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA): a meta-analysis of its clinical impact, molecular epidemiology, and diagnostic challenges across 15,165 isolates"],"prefix":"10.1186","volume":"26","author":[{"given":"Donghua","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"li","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"issue":"2","key":"13473_CR1","first-page":"269","volume":"90","author":"WA McGuinness","year":"2017","unstructured":"McGuinness WA, Malachowa N, DeLeo FR. Vancomycin Resistance in Staphylococcus aureus. Yale J Biol Med. 2017;90(2):269\u201381. PMID: 28656013.","journal-title":"Yale J Biol Med"},{"issue":"3","key":"13473_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1473-3099(01)00091-3","volume":"1","author":"K Hiramatsu","year":"2001","unstructured":"Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis. 2001;1(3):147\u201355. https:\/\/doi.org\/10.1016\/S1473-3099(01)00091-3.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"13473_CR3","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1086\/513203","volume":"44","author":"FC Tenover","year":"2007","unstructured":"Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44(9):1208\u201315. https:\/\/doi.org\/10.1086\/513203.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"13473_CR4","doi-asserted-by":"publisher","first-page":"116180","DOI":"10.1016\/j.diagmicrobio.2024.116180","volume":"108","author":"X Cheng","year":"2024","unstructured":"Cheng X, Ma L, Wang Y, Sun W, Su J. Prevalence and molecular characteristics of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of northern China. Diagn Microbiol Infect Dis. 2024;108(3):116180. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2024.116180.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"13473_CR5","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s10096-017-2956-1","volume":"36","author":"T Kim","year":"2017","unstructured":"Kim T, Kim ES, Park SY, et al. Phenotypic changes of methicillin-resistant Staphylococcus aureus during vancomycin therapy for persistent bacteraemia and related clinical outcome. Eur J Clin Microbiol Infect Dis. 2017;36(8):1473\u201381. https:\/\/doi.org\/10.1007\/s10096-017-2956-1.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"13473_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.meegid.2013.03.047","volume":"21","author":"BP Howden","year":"2014","unstructured":"Howden BP, Peleg AY, Stinear TP. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infect Genet Evol. 2014;21:575\u201382. https:\/\/doi.org\/10.1016\/j.meegid.2013.03.047.","journal-title":"Infect Genet Evol"},{"key":"13473_CR7","doi-asserted-by":"publisher","unstructured":"Yang CC, Sy CL, Huang YC, et al. Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility. Sci Rep. 2018;8(1):7868. Published 2018 May 18. https:\/\/doi.org\/10.1038\/s41598-018-26277-9.","DOI":"10.1038\/s41598-018-26277-9"},{"issue":"9","key":"13473_CR8","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1093\/jac\/dkaa221","volume":"75","author":"BE Castro","year":"2020","unstructured":"Castro BE, Berrio M, Vargas ML, et al. Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America. J Antimicrob Chemother. 2020;75(9):2424\u201331. https:\/\/doi.org\/10.1093\/jac\/dkaa221.","journal-title":"J Antimicrob Chemother"},{"key":"13473_CR9","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing\u2014 twenty-Nineth Edition: M100. 2019."},{"issue":"1","key":"13473_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1128\/JCM.01128-10","volume":"49","author":"SW Satola","year":"2011","unstructured":"Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol. 2011;49(1):177\u201383. https:\/\/doi.org\/10.1128\/JCM.01128-10.","journal-title":"J Clin Microbiol"},{"key":"13473_CR11","unstructured":"EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0. 2019."},{"key":"13473_CR12","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors. JBI manual for evidence synthesis. JBI, 2020. Available from https:\/\/synthesismanual.jbi.global\/10.46658\/JBIMES-20-08.","DOI":"10.46658\/JBIRM-17-06"},{"issue":"8","key":"13473_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529\u201336. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009.","journal-title":"Ann Intern Med"},{"issue":"9","key":"13473_CR14","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1093\/jac\/dku135","volume":"69","author":"TP Lodise","year":"2014","unstructured":"Lodise TP, Drusano GL, Lazariu V, et al. Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin. J Antimicrob Chemother. 2014;69(9):2547\u201355. https:\/\/doi.org\/10.1093\/jac\/dku135.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"13473_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ijantimicag","volume":"42","author":"JL Wang","year":"2013","unstructured":"Wang JL, Lai CH, Lin HH, Chen WF, Shih YC, Hung CH. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients. Int J Antimicrob Agents. 2013;42(5):390\u20134. https:\/\/doi.org\/10.1016\/j.ijantimicag.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"13473_CR16","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1128\/AAC.02820-13","volume":"58","author":"AM Casapao","year":"2014","unstructured":"Casapao AM, Davis SL, McRoberts JP, et al. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58(8):4636\u201341. https:\/\/doi.org\/10.1128\/AAC.02820-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"13473_CR17","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1128\/AAC.01365-08","volume":"53","author":"KC Horne","year":"2009","unstructured":"Horne KC, Howden BP, Grabsch EA, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother. 2009;53(8):3447\u201352. https:\/\/doi.org\/10.1128\/AAC.01365-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"13473_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3343\/alm.2016.36.3.235","volume":"36","author":"YR Koh","year":"2016","unstructured":"Koh YR, Kim KH, Chang CL, Yi J. Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients. Ann Lab Med. 2016;36(3):235\u201343. https:\/\/doi.org\/10.3343\/alm.2016.36.3.235.","journal-title":"Ann Lab Med"},{"issue":"9164","key":"13473_CR19","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/s0140-6736(99)01017-x","volume":"353","author":"J Ariza","year":"1999","unstructured":"Ariza J, Pujol M, Cabo J, et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet. 1999;353(9164):1587\u20138. https:\/\/doi.org\/10.1016\/s0140-6736(99)01017-x.","journal-title":"Lancet"},{"issue":"3","key":"13473_CR20","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1086\/381093","volume":"38","author":"PG Charles","year":"2004","unstructured":"Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38(3):448\u201351. https:\/\/doi.org\/10.1086\/381093.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"13473_CR21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s10096-009-0741-5","volume":"28","author":"RK Fong","year":"2009","unstructured":"Fong RK, Low J, Koh TH, Kurup A. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis. 2009;28(8):983\u20137. https:\/\/doi.org\/10.1007\/s10096-009-0741-5.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"13473_CR22","doi-asserted-by":"publisher","unstructured":"Neoh HM, Hori S, Komatsu M, et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob. 2007;6:13. Published 2007 Oct 30. https:\/\/doi.org\/10.1186\/1476-0711-6-13.","DOI":"10.1186\/1476-0711-6-13"},{"issue":"5","key":"13473_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1086\/596629","volume":"199","author":"Y Maor","year":"2009","unstructured":"Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis. 2009;199(5):619\u201324. https:\/\/doi.org\/10.1086\/596629.","journal-title":"J Infect Dis"},{"key":"13473_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/jpsic.jpsic_9_19","volume":"7","author":"P Batra","year":"2019","unstructured":"Batra P, Mathur P, Paul R, Gupta P, Malhotra R. Clinical profile of patients with heteroresistant vancomycin- intermediate Staphylococcus aureus bacteraemia compared to those with methicillinresistant Staphylococcus aureus bacteraemia at a level-1 trauma centre of India. J Patient Saf Infect Control. 2019;7:16\u20139. https:\/\/doi.org\/10.4103\/jpsic.jpsic_9_19.","journal-title":"J Patient Saf Infect Control"},{"issue":"11","key":"13473_CR25","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1128\/JCM.02024-12","volume":"50","author":"RE Mendes","year":"2012","unstructured":"Mendes RE, Deshpande LM, Smyth DS, Shopsin B, Farrell DJ, Jones RN. Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia. J Clin Microbiol. 2012;50(11):3694\u2013702. https:\/\/doi.org\/10.1128\/JCM.02024-12.","journal-title":"J Clin Microbiol"},{"issue":"9092","key":"13473_CR26","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(97)07324-8","volume":"350","author":"K Hiramatsu","year":"1997","unstructured":"Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997;350(9092):1670\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(97)07324-8.","journal-title":"Lancet"},{"issue":"1","key":"13473_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1128\/JCM.41.1.5-14.2003","volume":"41","author":"L Cui","year":"2003","unstructured":"Cui L, Ma X, Sato K, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol. 2003;41(1):5\u201314. https:\/\/doi.org\/10.1128\/JCM.41.1.5-14.2003.","journal-title":"J Clin Microbiol"},{"issue":"10","key":"13473_CR28","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1128\/AAC.43.10.2565","volume":"43","author":"M Backo","year":"1999","unstructured":"Backo M, Gaenger E, Burkart A, Chai YL, Bayer AS. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam. Antimicrob Agents Chemother. 1999;43(10):2565\u20138. https:\/\/doi.org\/10.1128\/AAC.43.10.2565.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"13473_CR29","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/sj.emboj.7600572","volume":"24","author":"E Huntzinger","year":"2005","unstructured":"Huntzinger E, Boisset S, Saveanu C, et al. Staphylococcus aureus RNAIII and the endoribonuclease III coordinately regulate spa gene expression. EMBO J. 2005;24(4):824\u201335. https:\/\/doi.org\/10.1038\/sj.emboj.7600572.","journal-title":"EMBO J"},{"issue":"2","key":"13473_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1086\/524667","volume":"46","author":"A Soriano","year":"2008","unstructured":"Soriano A, Marco F, Mart\u00ednez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193\u2013200. https:\/\/doi.org\/10.1086\/524667.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"13473_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1086\/346207","volume":"36","author":"SK Fridkin","year":"2003","unstructured":"Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997\u20132001. Clin Infect Dis. 2003;36(4):429\u201339. https:\/\/doi.org\/10.1086\/346207.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"13473_CR32","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1111\/j.1444-0903.2005.00986.x","volume":"35","author":"BP Howden","year":"2005","unstructured":"Howden BP. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Intern Med J. 2005;35(Suppl 2):S136\u201340. https:\/\/doi.org\/10.1111\/j.1444-0903.2005.00986.x.","journal-title":"Intern Med J"},{"issue":"2","key":"13473_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0732-8893(02)00511-4","volume":"45","author":"S Andrade-Baiocchi","year":"2003","unstructured":"Andrade-Baiocchi S, Tognim MC, Baiocchi OC, Sader HS. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization. Diagn Microbiol Infect Dis. 2003;45(2):149\u201352. https:\/\/doi.org\/10.1016\/s0732-8893(02)00511-4.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"13473_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1128\/CMR.00042-09","volume":"23","author":"BP Howden","year":"2010","unstructured":"Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23(1):99\u2013139. https:\/\/doi.org\/10.1128\/CMR.00042-09.","journal-title":"Clin Microbiol Rev"},{"key":"13473_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2180-8-39","volume":"8","author":"BP Howden","year":"2008","unstructured":"Howden BP, Smith DJ, Mansell A, et al. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol. 2008;8:39. https:\/\/doi.org\/10.1186\/1471-2180-8-39. Published 2008 Feb 27.","journal-title":"BMC Microbiol"},{"issue":"3","key":"13473_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4103\/tcmj.tcmj_145_17","volume":"30","author":"CY Lin","year":"2018","unstructured":"Lin CY, Wang JH, Lin KH, Ho YL, Ho CM. Methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in Taiwan. Tzu Chi Med J. 2018;30(3):135\u201340. https:\/\/doi.org\/10.4103\/tcmj.tcmj_145_17.","journal-title":"Tzu Chi Med J"},{"issue":"3","key":"13473_CR37","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1128\/JB.188.3.1120-1133.2006","volume":"188","author":"F McAleese","year":"2006","unstructured":"McAleese F, Wu SW, Sieradzki K, et al. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin. J Bacteriol. 2006;188(3):1120\u201333. https:\/\/doi.org\/10.1128\/JB.188.3.1120-1133.2006.","journal-title":"J Bacteriol"},{"issue":"2","key":"13473_CR38","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1128\/AAC.01009-08","volume":"53","author":"WE Rose","year":"2009","unstructured":"Rose WE, Leonard SN, Rossi KL, Kaatz GW, Rybak MJ. Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2009;53(2):805\u20137. https:\/\/doi.org\/10.1128\/AAC.01009-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"13473_CR39","doi-asserted-by":"publisher","first-page":"e0156924","DOI":"10.1371\/journal.pone.0156924","volume":"11","author":"M de la Pardos","year":"2016","unstructured":"de la Pardos M, Curry M, Berger J, et al. MRSA Causing Infections in Hospitals in Greater Metropolitan New York: Major Shift in the Dominant Clonal Type between 1996 and 2014. PLoS ONE. 2016;11(6):e0156924. https:\/\/doi.org\/10.1371\/journal.pone.0156924. Published 2016 Jun 7.","journal-title":"PLoS ONE"},{"issue":"3","key":"13473_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jac\/dkp241","volume":"64","author":"FC Tenover","year":"2009","unstructured":"Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother. 2009;64(3):441\u20136. https:\/\/doi.org\/10.1093\/jac\/dkp241.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"13473_CR41","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1086\/606027","volume":"200","author":"IG Bae","year":"2009","unstructured":"Bae IG, Federspiel JJ, Mir\u00f3 JM, et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis. 2009;200(9):1355\u201366. https:\/\/doi.org\/10.1086\/606027.","journal-title":"J Infect Dis"},{"issue":"12","key":"13473_CR42","doi-asserted-by":"publisher","first-page":"e0227009","DOI":"10.1371\/journal.pone.0227009","volume":"14","author":"YD Bakthavatchalam","year":"2019","unstructured":"Bakthavatchalam YD, Babu P, Munusamy E, et al. Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India. PLoS ONE. 2019;14(12):e0227009. https:\/\/doi.org\/10.1371\/journal.pone.0227009. Published 2019 Dec 30.","journal-title":"PLoS ONE"},{"key":"13473_CR43","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1128\/JCM.01435-10","volume":"49","author":"K Riederer","year":"2011","unstructured":"Riederer K, Shemes S, Chase P, Musta A, Mar A, Khatib R. Detection of intermediately vancomycinsusceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods. J Clin Microbiol. 2011;49:2147\u201350. https:\/\/doi.org\/10.1128\/JCM.01435-10.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"13473_CR44","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/mdr.2015.0004","volume":"21","author":"A Singh","year":"2015","unstructured":"Singh A, Prasad KN, Misra R, et al. Increasing Trend of Heterogeneous Vancomycin Intermediate Staphylococcus aureus in a Tertiary Care Center of Northern India. Microb Drug Resist. 2015;21(5):545\u201350. https:\/\/doi.org\/10.1089\/mdr.2015.0004.","journal-title":"Microb Drug Resist"},{"issue":"7","key":"13473_CR45","doi-asserted-by":"publisher","first-page":"e88122","DOI":"10.7759\/cureus.88122","volume":"17","author":"A Agarwal","year":"2025","unstructured":"Agarwal A, Singhal L, Kour I, Gupta P, Kaur N, Vasesi D, Gupta V. Prevalence and Detection of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus (hVISA) Among Clinical Isolates: A Comparative Evaluation of Screening Methods. Cureus. 2025;17(7):e88122. https:\/\/doi.org\/10.7759\/cureus.88122.","journal-title":"Cureus"},{"issue":"11","key":"13473_CR46","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1128\/JCM.01620-15","volume":"53","author":"R Khatib","year":"2015","unstructured":"Khatib R, Riederer K, Sharma M, Shemes S, Iyer SP, Szpunar S. Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation. J Clin Microbiol. 2015;53(11):3543\u20136. https:\/\/doi.org\/10.1128\/JCM.01620-15.","journal-title":"J Clin Microbiol"},{"issue":"6","key":"13473_CR47","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1128\/JCM.01435-10","volume":"49","author":"K Riederer","year":"2011","unstructured":"Riederer K, Shemes S, Chase P, Musta A, Mar A, Khatib R. Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods. J Clin Microbiol. 2011;49(6):2147\u201350. https:\/\/doi.org\/10.1128\/JCM.01435-10.","journal-title":"J Clin Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13473-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13473-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13473-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:44:38Z","timestamp":1785761078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13473-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13473"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13473-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1425"}}